International Journal of Hematology

, Volume 73, Issue 2, pp 194–198 | Cite as

Primary Chronic Myelofibrosis: Clinical and Prognostic Evaluation in 336 Japanese Patients

  • Takashi Okamura
  • Naoko Kinukawa
  • Yoshiyuki Niho
  • Hideaki Mizoguchi
Review Article


We retrospectively analyzed 336 patients with primary chronic myelofibrosis from 203 medical institutes in Japan. Notwithstanding their heterogeneous treatments, the median survival in 298 patients that could be evaluated was 10.0 years. Average age at onset was 60.7 years. Men were affected 1.4 times more frequently than women. The factors associated with shorter survival included anemia, leukocytosis/leukocytopenia, thrombocytopenia, and increased blasts in the peripheral blood, and sex (male), age (>60), and the presence of symptoms. A new scoring system based on the peripheral blood findings (hemoglobin [Hb] level, platelet count, and rate of blast formation) at initial diagnosis clearly correlated with survival rate. Accordingly, patients could be categorized into 3 groups by severity grading. Through stepwise multivariate survival analysis, the significant prognostic factors were identified as the severity grading based on the new scoring system (P = .0002), age (P = .0024), sex (P = .0153), and Hb (P = .0198). Chromosomal abnormalities were found in 58 of 154 patients (38%), although these did not influence survival.

Key words

Myeloproliferative disorder Prognostic factor Multivariate analysis Kaplan-Meier curve 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Manoharan M. Idiopathic myelofibrosis: a clinical review.Int J Hematol. 1998;68:355–362.CrossRefPubMedGoogle Scholar
  2. 2.
    Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis.Blood. 1978;51:189–194.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Kreipe H, Jaquet K, Felgner J, et al. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia.Blood. 1991;78:1814–1817.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Anger B, Janssen JW, Schrezenmeier H, et al. Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms.Leukemia. 1990;4:258–261.PubMedGoogle Scholar
  5. 5.
    Yan X-Q, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation.Blood. 1996;88:402–409.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Le Bousse-Kerdiles M-C, Chevillard S, Charpentier A, et al. Differential expression of transforming growth factor-b, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia.Blood. 1996;88:4534–4546.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.N Engl J Med. 1998;338:572–580.CrossRefPubMedGoogle Scholar
  8. 8.
    Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.Blood. 1996;88:1013–1018.PubMedGoogle Scholar
  9. 9.
    Cervantes F, Pereira A, Esteve J, et al. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis.Br J Haematol. 1997;97:635–640.CrossRefPubMedGoogle Scholar
  10. 10.
    Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis.Cancer. 1997;80:708–719.CrossRefPubMedGoogle Scholar
  11. 11.
    Hasselbalch H, Jensen BA. Prognostic factors in idiopathic myelofibrosis: a simple scoring system with prognostic significance.Eur J Haematol. 1990;44:172–178.CrossRefPubMedGoogle Scholar
  12. 12.
    Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.Br J Haematol. 1997;98:96–102.CrossRefPubMedGoogle Scholar
  13. 13.
    Manoharan A. Myelofibrosis: prognostic factors and treatment.Br J Haematol. 1988;69:295–298.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2001

Authors and Affiliations

  • Takashi Okamura
    • 1
  • Naoko Kinukawa
    • 2
  • Yoshiyuki Niho
    • 1
    • 3
  • Hideaki Mizoguchi
    • 4
  1. 1.First Department of Internal MedicineFaculty of Medicine, Kyushu UniversityJapan
  2. 2.Department of Medical Information ScienceFaculty of Medicine, Kyushu UniversityJapan
  3. 3.Chihaya HospitalTokyo Women’s Medical CollegeTokyoJapan
  4. 4.Department of HematologyTokyo Women’s Medical CollegeTokyoJapan

Personalised recommendations